A comparison of treosulfan and carboplatin in patients with ovarian cancer not suitable for treatment with cisplatin

INTERVENTION: 1. Carboplatin: 6 x (glomerular filtration rate (GFR)+ 25) mg intravvenous every 28 days for six cycles 2. Treosulfan: 7 g/m2 intravenous every 28 days for six cycles CONDITION: Ovarian cancer ; Cancer ; Ovarian PRIMARY OUTCOME: Not provided at time of registration SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Not considered for cisplatin =75 mg/m2 2. Stages Ic‐IV 3. Histologically proven epithelial ovarian cancer 4. Life expectancy .3 months 5. World Health Organisation (WHO) Performance status 0‐3 6. Creatinine clearance =20 ml/min White Blood Cell (WBC) Count =3.5 x 10^9/l Platelets =100 x 10^9/l